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Focal and segmental glomerulosclerosis (FSGS) is a
histological pattern that has several etiologies, including
genetics. The autosomal dominant form of FSGS is a
heterogenic disease caused by mutations within three known
genes: a-actinin 4 (ACTN4), canonical transient receptor
potential 6 (TRPC6), and the inverted formin 2 (INF2) gene.
More recently, INF2 mutations have also been attributed
to Charcot–Marie–Tooth neuropathy associated with FSGS.
Here we performed direct sequencing, histological
characterization, and functional studies in a cohort of families
with autosomal dominant FSGS. We detected a novel
mutation in exon 6 of the INF2 gene outside of the exon 2–4
candidate region used for rapid diagnosis of autosomal
dominant FSGS. This new mutation is predicted to alter a
highly conserved amino-acid residue within the 17th a-helix
of the diaphanous inhibitory domain of the protein. A long-
term follow-up of this family indicated that all patients were
diagnosed in adulthood, as opposed to early childhood, and
progression to end-stage renal disease was at different times
without clinical or electrodiagnostic evidence of neuropathy.
Thus, this novel mutation in INF2 linked to nonsyndromic
FSGS indicates the necessity for full gene sequencing if
no mutation is found in the current rapid-screen region
of the gene.
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Focal and segmental glomerulosclerosis (FSGS) is a histological
pattern with different etiologies: primary (idiopathic) and
secondary (i.e., those forms with known etiology).1 The clinical
pattern is characterized by heavy proteinuria, nephrotic
syndrome, and the progressive loss of renal function,
probably resulting in end-stage renal disease (ESRD) and
renal replacement therapy. There has been a significant effort
to classify both the etiology and pathology of FSGS; however,
given its variable manifestations, physicians and researchers
continue to struggle to understand the molecular mechanisms
of the disease.1–4
Familial forms of FSGS account for up to 18% of all cases,5
and the vast majority of these cases present with early
childhood onset, whereas adult onset is very uncommon.
The clinical spectrum is strongly influenced by the type of
inheritance pattern. Indeed, autosomal recessive FSGS
usually manifests as a severe phenotype with an early onset
in neonates and young children, whereas the autosomal
dominant FSGS (AD-FSGS) form is generally associated with
a juvenile or adult onset. Several genes have been implicated
with both autosomal recessive FSGS (NPHS1-encoding
nephrin,6 NPHS2-encoding podocin,7 and PLCE1-encoding
phosphoinositide-specific phospholipase C epsilon-18) and
AD-FSGS (ACTN4-encoding alpha-actinin 49 and TRPC6-
encoding canonical transient receptor potential 610,11).
Recently, Brown et al.12 described a new locus for AD-FSGS
on chromosome 14q32 that includes the inverted formin 2
(INF2) gene. To date, approximately 15% of screened AD-FSGS
cases (n¼ 194) have been linked to mutations in INF2.12–15
More recently, Boyer et al.16 discovered that mutations in INF2
are also responsible for Charcot–Marie–Tooth (CMT) neuro-
pathy associated with FSGS. In both cases, mutations associated
with the syndromic and nonsyndromic form of the disease are
clustered in exons 2 to 4 of INF2, which encode the diaphanous
inhibitory domain (DID). However, most syndromic mutations
are localized between two putative DID-binding pockets coded
by the 30 end of exon 2 and 3, affecting DID function more
severely than mutations related to the nonsyndromic disease.
Exons 2–4 has been suggested as a rapid screening method
http://www.kidney-international.org c l in i ca l inves t iga t ion
& 2012 International Society of Nephrology
Correspondence: Maria Sanchez-Ares, Laboratory of Nephrology, Sanitary
Research Institute, University Clinical Hospital, Santiago de Compostela,
Spain. E-mail: maria.sanchez.ares@gmail.com or Miguel A. Garcia-Gonzalez,
Laboratory of Nephrology, Sanitary Research Institute (IDIS) or Department
of Neurology, University Clinical Hospital (CHUS), SERGAS, Santiago de
Compostela, Spain. E-mail: miguel.garcia.gonzalez@sergas.es
4Deceased
Received 1 February 2012; revised 24 July 2012; accepted 26 July 2012;
published online 12 September 2012
Kidney International (2012) 83, 153–159 153
for the diagnosis of both AD-FSGS15 and CMT with
glomerulopathy.16 The DID domain allows INF2 to accelerate
the polymerization and depolymerization of actin filaments and
regulate specialized routes of protein targeting to the plasma
membrane by forming protein complexes with Rho-GTPases,
CDC42, and myelin and lymphocyte (MAL) protein, or MAL2
in podocytes and Schwann cells.16–18 The main objective of this
study is to conduct correlation studies in our cohort of Spanish
AD-FSGS families. Although very little is known about INF2,
the information provided by the mutational analysis in patients
will help us improve our understanding of its functions and the
pathogenesis of FSGS and CMT.
RESULTS
Clinical observations
We performed mutational analysis for AD-FSGS genes in five
families (19 affected and 108 unaffected individuals) with a
presumably autosomal dominant mode of inheritance of
FSGS with two or more affected individuals in at least two
generations.15 Patients were classified following the inclusion
criteria described below (Materials and Methods section).
The age of diagnosis, maximum proteinuria levels, the
presence of microhematuria and/or arterial hypertension,
age at ESRD, and recurrence after transplant of affected
individuals are presented in Supplementary Table S1 online.
Initial mutational analyses for ACTN4 and TRPC6 were
negative (sequence variants are shown in Supplementary
Table S2 online). After the discovery by Brown et al.12 that
INF2 mutations cause FSGS, we expanded our mutational
analysis to this gene and identified a novel point mutation
(L245P) in the CHUS_FSGS-2 family (see Supplementary
Table S2 online for INF2 sequence variants).
The proband of CHUS_FSGS-2 is a 21-year-old man
(Figure 1 and Table 1, III:2) who had elevated blood urea,
proteinuria in a nephrotic range, and microhematuria in a
health maintenance visit; therefore, he was immediately
referred to our hospital. Upon admission, he had an elevated
blood pressure (170/110 mm Hg) with normal cardiothoracic
and abdominal examinations. Blood tests showed abnormal
levels of hemoglobin (10.7 g/dl), total plasma protein content
(5.7 g/dl), albumin (3.3 g/dl), urea (125 mg/dl), creatinine
(4.5 mg/dl), cholesterol (438 mg/dl), and triglycerides
(253 mg/dl). Urinalysis confirmed a nephrotic-range protei-
nuria (7 g/l) and microhematuria. Renal ultrasound showed
small kidneys (left, 80 mm; right, 85 mm) with hyperecho-
genic parenchyma.
On light microscopy, renal biopsy revealed FSGS with
advanced glomerular damage. Several glomeruli already
showed solidification of the entire tuft or global sclerosis.
Severe tubulointerstitial injuries were also observed in areas
of advanced tubular atrophy and interstitial fibrosis. Electron
microscopy revealed extensive foot process effacement of
podocytes without electron-dense deposits (data not shown).
We continued to follow-up the patient and observed that
his renal function progressively declined. Within 6 months,
he progressed to ESRD and underwent hemodialysis. A
cadaveric renal transplant was performed at the age of 23.
After a follow-up of 13 years post renal transplant (at the age
of 36), there were no signs of FSGS recurrence. Given that
INF2 mutations can be associated with CMT,16 a complete
clinical neurological evaluation was performed. The patient
did not complain of numbness or weakness. Neurological
examinations did not show signs of peripheral neuropathy,
and pes cavus was not found. In addition to this, results of
motor and sensory nerve conduction studies in the upper
and lower limbs were normal.
Further analysis of the proband’s family history revealed
that his father and his brother (Figure 1, II:3 and III:3,
respectively) also suffered from renal disease. The father was
diagnosed at the age of 26 with advanced-stage renal failure,
in addition to having symptoms of severe fatigue, polyuria,
and high urea levels. Emergency hemodialysis was performed,
but he died a few days later from technical complications.
Clinical records for the proband’s brother (III:3) started
at the age of 28 when elevated proteinuria was detected. He
was referred to our hospital where a physical examination
showed exclusively high blood pressure (155/80 mm Hg).
Blood tests revealed hypercholesterolemia (293 mg/dl)
and normal renal function (urea and creatinine levels of 31
and 1.2 mg/dl, respectively). A urinalysis showed normal
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8 II:9 II:10 II:11
I:1 I:2
III:1 III:2 III:3 III:4 III:5 III:6 III:7 III:8 III:9 III:10
ESRD
(26 years)
ESRD
(22 years)
ESRD
(35 years)
Key:
Unaffected Affected Deceased Unknown
Figure 1 | Pedigree of the CHUS_FSGS-2 family with the mutation L245P. ESRD, end-stage renal disease.
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urine sediment with elevated levels of proteinuria (7.8 g/l);
the renal ultrasound was normal, and subsequently a renal
biopsy was performed.
Light microscopic findings for patient III:3 demonstrated
glomerular lesions characteristic of FSGS. Electron micro-
scopy exhibited diffuse foot process effacement in all capillary
loops. We also observed nonspecific ultrastructural changes
in the mesangium and basal lamina, with irregular thickness
of the subendothelial space, incipient widening, and
duplication of the basal lamina. In some glomerular areas,
a few granular and round particles were found in the
mesangium and basal lamina (Figure 2). Immunofluorescent
microscopy using glomerular markers detected focal and
segmental deposits of C3 and mesangial IgM, with negative
results for other immunoglobulins and complement fractions
(data not shown).
Initially, a prolonged oral steroid treatment (1.5 mg/kg/
day for 6 months) had no effect on his proteinuria, and his
disease was considered steroid resistant. Subsequently, patient
III:3 was treated with cyclosporine A (starting dose: 3 mg/kg
bw/day, maintaining the trough level between 80 and
100 ng/ml) for 18 months; however, this treatment was also
ineffective in reducing proteinuria levels. In addition, patient
III:3 was treated with simvastatin for hypercholesterolemia
and lisinopril for arterial hypertension. Lisinopril did not
have an antiproteinuric effect. The patient’s renal function
progressively decreased, reaching ESRD 7 years after renal
biopsy, and the patient started hemodialysis at the age of 35.
Two years later, patient III:3 received a cadaveric renal
transplant, and after 6 years of follow-up, his renal function
remains normal with no signs of proteinuria. Neurological
examinations and sensory and motor nerve conduction
studies in upper and lower limbs were normal, without
evidence of peripheral neuropathy.
Genetic analysis of INF2
From the AD-FSGS families in our cohort, we only found the
disease associated with the novel INF2 variant in one family
(CHUS_FSGS-2). This mutation consists of a thymine-to-
cytosine nucleotide substitution at exon 6 (c.734T4C),
which is predicted to substitute a leucine residue for a proline
residue in the INF2 protein (p.L245P, Figure 3a). To ensure
segregation with AD-FSGS, we confirmed that the L245P
mutation was carried only by the affected family members
and was not present in unaffected members (II:2, II:4, II:6,
II:8, II:11, and III:10). In addition, this mutation was not
identified in our control chromosomes or in public single-
nucleotide polymorphism databases and the 1000 Genome
Project. Supplementary Table S2 online shows a number of
novel and previously described polymorphisms detected in
our cohort of AD-FSGS families.
Molecular characterization and structural modeling of L245P
The mutation c.846T4C is located within the DID domain
of INF2 (Figure 3b) and is an evolutionarily highly conserved
residue between humans, chimpanzees, mice, and zebrafish
INF2; human diaphanous-related formin 1; and mouse
diaphanous-related formin 1 (mDia1) (Figure 3c). In addi-
tion, PolyPhen-2 predicts the pathogenicity of L245P to be
‘Probably Damaging,’ with a score of 0.979 (sensitivity: 0.67;
specificity: 0.94),19 and Sorting Tolerant From Intolerant
(SIFT) software found this mutation to be harmful, with a
score of 0.03.20
Structural analysis predicts that the L245P mutation alters
the architecture of the 17th a-helix (amino acids 239–264) of
the DID domain by causing a turn point and forcing a bend of
approximately 301 in the helix axis of this domain (Figure 4).
DISCUSSION
AD-FSGS is an uncommon form of familial FSGS that usually
affects juvenile and adult patients, presenting as late-onset
proteinuria and often leading to ESRD. Mutations in ACTN4
and TRPC6 have been associated with 7% of all screened cases
of AD-FSGS.5,9,10,21–23 Recently, mutations in exons 2 to 4 of
the INF2 gene have been linked to AD-FSGS nephropathy and
CMT neuropathy associated with FSGS. Interestingly, many of
these are recurrent mutations (15 novel and10 recurrent
mutations) with variable renal and neurological pheno-
types.12–16 In this study, we describe the genetic screening
and phenotypic analysis of a cohort of five families with
Table 1 | Phenotypes of affected patients in the CHUS_FSGS-2
family
II:3 III:2 III:3
Age at diagnosis (years) 26 21 28
Maximal proteinuria (g/l) N/A 7 7.8
Microhematuria N/A Yes No
Arterial hypertension N/A Yes Yes
Steroid response Untreated Untreated Resistant
Cyclosporine response Untreated Untreated Unresponsive
Age at ESRD (years) 26 22 35
Renal transplantation No Yes Yes
Recurrence post
transplantation
— Not after
13 years
Not after
6 years
Abbreviations: ESRD, end-stage renal disease; N/A, not available.
END cell
MES cell
Figure 2 | Histopathological findings of the CHUS_FSGS-2 patient
III:3. (a) Focal segmental distribution of glomerular lesions. The
involved glomerulus shows a dense segmental scar. A monolayer of
podocytes overlies the sclerotic segment. The sclerosis glomerular
area is crowned by podocytes (arrows). Periodic acid Schiff original
magnification 400. (b) The ultrastructure study shows hyperplasic
podocytes with foot effacement and continuous podocyte
effacement (arrows). Subendothelial widening and irregularity
without dense deposits are apparent. Original magnification 7500.
END cell, endothelial cell; MES cell, mesangial cell.
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AD-FSGS. After negative mutational analysis for ACTN4 and
TRPC6, we found that one family carries a novel missense
mutation (L245P) in exon 6 of INF2. We report the first novel
mutation outside the candidate region for diagnosis of INF2,
highlighting the need to sequence the entire gene if no
mutations are found in exons 2 to 4. Furthermore, FSGS
patients carrying the L245P mutation have no clinical or
electrodiagnostic evidence of associated neuropathy,
suggesting exon 6 as a region for nonsyndromic FSGS.
Mutations in autosomal recessive genes NPHS1, NPHS2,
CD2AP, and PLCE1 have been associated with severe FSGS,
whereas mutations in ACTN4, TRPC6, and INF2 have been
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Figure 3 | Localization and evolutionary conservation of mutations in inverted formin 2 (INF2) gene. (a) Electropherogram showing the
novel mutation (L245P) in exon 6 of INF2 in the CHUS_FSGS-2 family. (b) Schematic representation showing exons 2–8 of the INF2 gene and
INF2 protein domain structure. The genomic and protein locations of L245P mutation are shown. All previously described INF2 mutations fall
into the diaphanous inhibitory domain (DID), codified by exons 2–4 (dark green). L245P is the first mutation found outside this hotspot.
The number of recurrent mutational events is indicated in parentheses. (c) Alignment of the N-terminal sequences of human, chimpanzee,
mouse, and zebrafish INF2; human diaphanous-related formin 1 (DIAPH1); and mouse diaphanous-related formin 1 (mDia1). INF2 mutations
previously identified in patients with autosomal dominant focal and segmental glomerulosclerosis (AD-FSGS) alone are shown in yellow. INF2
mutations identified in patients with Charcot–Marie–Tooth (CMT) neuropathy associated with FSGS are shown in blue. The amino acid affected
by the L245P mutation (red) is evolutionarily well conserved across species, as are the previously described mutations. The secondary protein
structure of mDia1 is illustrated to localize the position of the mutations. Most of the mutations are in the a-helices. L245P is the first mutation
described out of the armadillo repeats associated with FSGS alone and CMT neuropathy associated with FSGS. DAD, diaphanous
autoregulatory domain; FH, formin homology; WT, wild type.
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associated with a later-onset form of the disease.24 All of
the variants were found in podocyte genes that code
for structural elements located in the glomerular slit
diaphragm25 and in proteins involved in the maintenance
of the podocyte actin cytoskeleton. With the additional
association of INF2 mutations with AD-FSGS, the
understanding of this disease has increased. Mutations in
the INF2 gene are major causes of familial AD-FSGS, with a
prevalence of approximately 15% of all screened families in
the world (n¼ 195, including the one described in this
article). This prevalence is in clear contrast to the
contribution of mutations in TRPC6 (5.5%)9–11,21–23 and
ACTN4 (1.5%).5,9 A total of 69.3% (n¼ 27) of all INF2
mutations previously identified cause nonsyndromic FSGS
(exon 4: 61.5%, n¼ 24; exon 2: 7.7%, n¼ 3), whereas the
remaining 30.7% result in syndromic FSGS (exon 2: 17.9%,
n¼ 7; exon3: 12.8%, n¼ 5). Another distinctive characteristic
of the INF2 gene is its ability to inherit recurrent mutations
(23.8%) when compared with the ACTN4 and TRPC6 genes
(none), which is a unique characteristic among the AD-FSGS
genes (Figure 3b).12–16 Both aspects have led researchers to
suggest that exons 2–4 of INF2 are candidate regions for a
rapid, noninvasive, and cost-effective mutational screening
for diagnosing AD-FSGS linked to INF2 gene.14,15
The INF2 protein is a member of the formin family of
actin-regulatory proteins and has the following domains: a
domain structure resembling an N-terminal DID17; formin
homology 1 and 2 domains26,27; and a C-terminal WASP
Homology 2 domain, which has the hallmarks of the
diaphanous autoregulatory domain (DAD) present in other
formins (Figure 3b).17 The DID binds to the DAD, which
autoinhibits the depolymerization but not the polymerization
activity of INF2; this action is in contrast to other formins,
where the DID/DAD binding inhibits both activities. Recently,
Chhabra et al.28 discovered that INF2 is predominantly
localized in the endoplasmic reticulum and that mutations
disrupting the DID/DAD interaction cause the endoplasmic
reticulum to collapse because of the accumulation of actin
filaments. When the DID/DAD interaction does not occur,
actin polymerization is deregulated, which blocks the
interaction of the INF2 protein with the formins of the DIA
(diaphanous) group and alters the transport processes
(transcytosis) mediated by the MAL protein and the MAL
proteolipid protein 2 (MAL2).29,30 Interestingly, all INF2
mutations were found in exons coding for the DID.12–16
Nature provides numerous examples of associations between
mutations and phenotypes. Therefore, mutational screenings
of affected individuals can help us generate databases of
variations, which will be an invaluable tool to study the
important functional domains. In particular, missense
mutations are very important when studying specific
residues and their critical functional properties.
The INF2 gene was studied in our cohort after excluding
ACTN4 and TRPC6. Affected individuals in the
CHUS_FSGS-2 family carried a nucleotide change in exon
6 that segregated with the disease. This change resulted in the
substitution of the amino acid leucine to proline at position
245 (L245P) located within a highly conserved region on the
17th a-helix of the DID. In addition, the PolyPhen and SIFT
software predicted that the change (L245P) would be highly
pathogenic. Structurally, leucine and proline are two very
different amino acids. The replacement of leucine residues
with proline disturbs protein folding and commonly causes a
turn point, resulting in a major conformational change.31
Furthermore, proline is rarely found in a and/or b structures,
as it would reduce the stability of such structures32 because of
A13
L42
L57
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Y193
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L245 R214
R216
E220
R177
L165
A164
S186
E184
L132
L128
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30°
Figure 4 | Three-dimensional model of the diaphanous inhibitory domain (DID) of human inverted formin 2 (INF2). (a) View of the
DID based on the structure of mouse diaphanous-related formin 1 (mDia1). Amino acids 1 through 330 of INF2 (corresponding to amino
acids 46 through 440 of mDia1) are shown. The positions of the altered residues identified for autosomal dominant focal and segmental
glomerulosclerosis (AD-FSGS) alone and Charcot–Marie–Tooth neuropathy associated with FSGS are presented in yellow and blue, respectively.
The residue variant (L245P) identified in this study is shown in red, and it is located at 17th a-helix of the DID. (b) The proline substitution
forces a bend of approximately 301 in the 17th a-helix of the DID. The wild-type 17th a-helix is boxed. When leucine is substituted for
proline (red), the conformational structure of the wild-type helix (gray) is bent 301 (green) because proline cannot donate an amide hydrogen
bond, and its side chain interferes sterically with the backbone of the preceding turn.
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its a-N side chain, which can only act as a hydrogen bond
acceptor.31 Therefore, we inferred the impact of the L245P
mutation, which would markedly alter the structure and
possibly the function of the 17th a-helix of the DID domain
(Figure 4b). The 17th a-helix is predicted to establish the
initial weak interaction between the homolog of DID and
Rho, permitting a second tighter interaction between them
that then allows for the initialization of actin polymerization
by the release of the DID/DAD complex.16 Rose et al.33
predicted that this a-helix constitutes the interdomain helix
located between the armadillo repeats, the dimerization
domain, and amino acids 347–377 of mDia1. In contrast,
Otomo et al.34 define this region as the second alpha helix of
the fifth truncated armadillo repeat, amino acids 347–367 of
mDia1. The vast majority of INF2 mutations are in a-helices
(77% of the mutations described to date). Mutations within
a-helices of the fourth armadillo repeat are only associated
with FSGS, whereas mutations causing FSGS-associated CMT
neuropathy are mostly located within a-helices of the second
and third armadillo repeat.
The onset and severity of the phenotypes are extremely
variable for individuals affected with FSGS in the
CHUS_FSGS-2 family given that they share the same
mutation. The proband III:2 and his father II:3 were
diagnosed in adulthood (21 and 26 years of age, respectively)
with advanced clinical manifestations of the disease and rapid
progression to ESRD (1 and 6 months, respectively),
suggesting an early onset of the disease. On the other hand,
the proband’s brother (III:3) had the adulthood-onset version
of the disease (age of 28), with normal levels of creatinine and
a moderate progression to ESRD (7 years later). This
variability may be explained either by stochastic effects or
genetic modifiers. The phenotypic presentation of many renal
disorders is strongly influenced by the genetic environment.
For example, other researchers and our group have shown that
genetic interactions between dominant and recessive forms
of polycystic kidney disease (PKD) can lead to a severe
phenotype.35 Therefore, we cannot rule out the fact that
sequence variants in other FSGS genes or its downstream
targets could modulate the severity and/or variability
associated with the INF2 mutations. Despite this phenotypic
variability, we provide further understanding of the disease
and its relation to INF2 function. Mutations in this new region
of INF2 are associated with nonsyndromic FSGS. Future
studies should be directed at identifying new candidate genes
of AD-FSGS to establish genotype–phenotype correlations
in large FSGS cohorts. These studies would facilitate the
understanding of the pathology and progression of the disease.
In conclusion, this study describes a mutational screening
in a cohort of Spanish families with AD-FSGS. We identified
a novel missense mutation (L245P) in exon 6 of the recently
discovered disease-associated gene INF2. Although previous
publications suggested exons 2 to 4 as the regions for
diagnostic mutational screening, this study reveals that AD-
FSGS mutations can be found beyond these exons. Because
the location of the mutation in INF2 may be related to
disease manifestation (exons coding for the second and third
DID armadillo repeats are associated with FSGS and CMT,
whereas exons coding the fourth armadillo repeat are
associated with FSGS alone), we describe a new protein
region (17th a-helix of DID) responsible for AD-FSGS
without neuropathy.
MATERIALS AND METHODS
Patients and data recruitment
The inclusion criteria are as follows: (i) renal biopsy demonstrating
FSGS; (ii) substantial proteinuria; (iii) exclusion of secondary causes
of FSGS; and (iv) exclusion of idiopatic or autosomal recessive FSGS
(two or more affected individuals in one generation). Age at FSGS
onset, course of glomerular disease, age at ESRD onset, kidney
histology, and transplantation outcomes were obtained for each
patient. The clinical characteristics are collected in Table 1. All
participants were informed of the goal of the study, and consent was
obtained in accordance with the local ethical committee (Galician
Clinical Investigation Committee) and the Helsinki Declaration.
Electrodiagnostic testing
Nerve conduction studies were conducted using standard techniques
36 of surface stimulation and recording on a Nicolet Viking IV EMG
equipment (Nicolet Biomedical Instruments, Madison, WI). Skin
temperatures were maintained higher than 32.0 1C. Distal motor
latency, F-wave latency, motor nerve conduction velocity, and
compound motor action potential were measured in the median,
ulnar, peroneal, and posterior tibial nerves. Sensory nerve
conduction velocity and sensory nerve action potential were
obtained in the median, ulnar, and sural nerves. Electromyography
was performed in tibialis anterior and medial gastrocnemius muscles.
DNA isolation and mutation analysis
Genomic DNA was isolated from peripheral blood samples using the
QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s guidelines. We performed mutational analysis by
PCR amplification of all exons and flanking regions of ACTN4,
TRPC6, and INF2 using the BioMix kit (Bioline, London, UK) and
following the strategy described in Supplementary Table S3 online.
Primers were designed with Primer3 (http://frodo.wi.mit.edu/
primer3/). Sequencing reactions were performed using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Warrington, UK). Sequencing was carried out using the ABI
3130xl Genetic Analyzer (Applied Biosystems) and analyzed by
using the DNA Sequencing Analysis Software v5.2 (Applied
Biosystems).
In silico prediction of amino-acid substitution L245P
The nonsynonymous sequence variants of genes were analyzed
with the PolyPhen-2 software (http://genetics.bwh.harvard.edu/
pph2/index.shtml)19 and SIFT algorithm (http://sift.jcvi.org)20 to
predict the impact of the amino-acid substitution. Polyphen-2
calculates a Naı¨ve Bayes posterior probability that any mutation
is damaging by the representation of a score ranging from 0 to 1,
as well as providing a qualitative damage based on the model’s false-
positive rate (benign, possibly damaging, or probably damaging).
SIFT prediction is based on the degree of conservation of amino-
acid residues in sequence alignments derived from closely related
sequences providing a qualitative damage as well (tolerated or
damaging).
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Structural analysis for L245P mutation
Following the approach described by Brown et al,12 we manipulated
the DID domain model using the PyMol software (www.pymol.org)
and identified the residues in mDia1 corresponding to our FSGS-
novel mutation and the ones previously associated by others with
the DID domain. In addition, we predicted the functional impact
of our mutation constructing the wild-type and the mutant 17th
a-helix of the DID domain by using the PyMol software as well.
Web resources
The following GenBank sequences (http://www.ncbi.nlm.nih.gov/
Genbank/) served as reference files: NG_027684 for INF2 genomic
nucleotide position, NM_022489 for INF2 cDNA position. Uni-
ProtKB (http://www.uniprot.org/help/uniprotkb, ID: Q27J81) and
the Ensembl Genome Browser (http://www.ensembl.org, ID:
ENSP00000376410) were used to determine the INF2 amino-acid
position and ClustalW (http://www.ebi.ac.uk/clustalw/) for multiple
sequence alignment.
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